ARTICLE | Company News
Shire licenses IBD biologic from Pfizer
June 15, 2016 12:23 AM UTC
Pfizer Inc. (NYSE:PFE) granted Shire plc (LSE:SHP; NASDAQ:SHPG) global rights to inflammatory bowel disease (IBD) candidate PF-00547659. Deal terms were not disclosed.
The mAb targeting mucosal vascular addressing cell adhesion molecule 1 ( MAdCAM-1) has completed Phase II studies for ulcerative colitis and Crohn's disease. Shire spokesperson Clotilde Houze said the company is designing the Phase III program for PF-00547659, with studies expected to start after discussions with regulators. ...